Stock Price

2.810 KRW

-6.96% ROA

-9.22% ROE

-11.56x PER

Market Cap.

244.991.990.100 KRW

0% DER

0% Yield

-24.81% NPM

LabGenomics Co., Ltd. Stock Analysis

LabGenomics Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

LabGenomics Co., Ltd. Fundamental Stock Analysis
# Analysis Rating

LabGenomics Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

LabGenomics Co., Ltd. Technical Stock Analysis
# Analysis Recommendation

LabGenomics Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

LabGenomics Co., Ltd. Revenue
Year Revenue Growth
2019 33.175.358.670
2020 119.478.053.820 72.23%
2021 202.407.363.610 40.97%
2022 144.772.745.630 -39.81%
2023 73.126.594.640 -97.98%
2024 88.922.844.000 17.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

LabGenomics Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2019 0
2020 0 0%
2021 556.873.000 100%
2022 1.864.884.000 70.14%
2023 2.812.251.000 33.69%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

LabGenomics Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 534.659.000
2020 1.602.796.000 66.64%
2021 2.025.952.000 20.89%
2022 2.684.523.000 24.53%
2023 2.774.752.000 3.25%
2024 45.588.772.000 93.91%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

LabGenomics Co., Ltd. EBITDA
Year EBITDA Growth
2019 4.885.066.360
2020 57.418.125.480 91.49%
2021 110.507.475.360 48.04%
2022 72.681.337.980 -52.04%
2023 2.857.341.100 -2443.67%
2024 33.983.108.000 91.59%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

LabGenomics Co., Ltd. Gross Profit
Year Gross Profit Growth
2019 12.948.166.150
2020 71.749.994.150 81.95%
2021 125.410.910.420 42.79%
2022 96.766.740.860 -29.6%
2023 32.393.889.560 -198.72%
2024 33.983.108.000 4.68%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

LabGenomics Co., Ltd. Net Profit
Year Net Profit Growth
2019 962.421.370
2020 42.766.441.520 97.75%
2021 83.854.993.820 49%
2022 48.397.233.060 -73.26%
2023 -4.673.917.770 1135.47%
2024 904.884.000 616.52%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

LabGenomics Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 16
2020 649 97.69%
2021 414 -57.14%
2022 715 42.16%
2023 -63 1233.33%
2024 12 625%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

LabGenomics Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2019 2.627.145.470
2020 44.856.776.280 94.14%
2021 51.547.428.180 12.98%
2022 30.624.729.310 -68.32%
2023 -9.023.299.390 439.4%
2024 -8.058.266.470 -11.98%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

LabGenomics Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2019 3.188.085.830
2020 46.371.796.050 93.12%
2021 65.361.945.920 29.05%
2022 68.954.535.330 5.21%
2023 -3.826.988.570 1901.8%
2024 -6.651.950.920 42.47%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

LabGenomics Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2019 560.940.360
2020 1.515.019.770 62.97%
2021 13.814.517.740 89.03%
2022 38.329.806.020 63.96%
2023 5.196.310.820 -637.63%
2024 1.406.315.550 -269.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

LabGenomics Co., Ltd. Equity
Year Equity Growth
2019 30.417.447.500
2020 81.640.387.420 62.74%
2021 158.421.278.130 48.47%
2022 210.510.338.820 24.74%
2023 228.142.698.600 7.73%
2024 225.708.715.000 -1.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

LabGenomics Co., Ltd. Assets
Year Assets Growth
2019 49.477.979.240
2020 109.363.615.820 54.76%
2021 204.286.591.530 46.47%
2022 250.652.717.020 18.5%
2023 313.457.035.500 20.04%
2024 304.446.590.000 -2.96%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

LabGenomics Co., Ltd. Liabilities
Year Liabilities Growth
2019 19.060.531.740
2020 27.723.228.410 31.25%
2021 45.865.313.400 39.56%
2022 40.142.378.190 -14.26%
2023 85.314.336.880 52.95%
2024 78.737.875.000 -8.35%

LabGenomics Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1150.6
Net Income per Share
-285.49
Price to Earning Ratio
-11.56x
Price To Sales Ratio
2.87x
POCF Ratio
-24.76
PFCF Ratio
-19.39
Price to Book Ratio
1.08
EV to Sales
2.87
EV Over EBITDA
26.57
EV to Operating CashFlow
-24.78
EV to FreeCashFlow
-19.39
Earnings Yield
-0.09
FreeCashFlow Yield
-0.05
Market Cap
245 Bil.
Enterprise Value
245 Bil.
Graham Number
4421.22
Graham NetNet
-1061.57

Income Statement Metrics

Net Income per Share
-285.49
Income Quality
0.53
ROE
-0.09
Return On Assets
-0.07
Return On Capital Employed
-0.08
Net Income per EBT
0.89
EBT Per Ebit
1.26
Ebit per Revenue
-0.22
Effective Tax Rate
0.09

Margins

Sales, General, & Administrative to Revenue
0.3
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.37
Operating Profit Margin
-0.22
Pretax Profit Margin
-0.28
Net Profit Margin
-0.25

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-133.28
Free CashFlow per Share
-170.31
Capex to Operating CashFlow
-0.28
Capex to Revenue
0.03
Capex to Depreciation
0.39
Return on Invested Capital
-0.08
Return on Tangible Assets
-0.07
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
37.03

Balance Sheet

Cash per Share
0,00
Book Value per Share
3.043,09
Tangible Book Value per Share
3043.09
Shareholders Equity per Share
3043.09
Interest Debt per Share
52.12
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
1.97
Tangible Asset Value
226 Bil.
Net Current Asset Value
71 Bil.
Invested Capital
73625595000
Working Capital
74 Bil.
Intangibles to Total Assets
0
Average Receivables
17 Bil.
Average Payables
4 Bil.
Average Inventory
1179450065
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

LabGenomics Co., Ltd. Dividends
Year Dividends Growth
2021 1.800

LabGenomics Co., Ltd. Profile

About LabGenomics Co., Ltd.

CEO
Employee
0
Address

,

LabGenomics Co., Ltd. Executives & BODs

LabGenomics Co., Ltd. Executives & BODs
# Name Age

LabGenomics Co., Ltd. Competitors